An observational study in Germ Cell Tumor, Metachronous Malignant Neoplasm and Seminoma, sponsored by SWOG Cancer Research Network. Active, not recruiting at 424 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by SWOG Cancer Research Network · Observational
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
PRIMARY OBJECTIVE:
I. To estimate the positive predictive value within each of the early stage testicular seminoma and nonseminoma groups using plasma miRNA 371 expression at relapse to detect germ cell malignancy.
SECONDARY OBJECTIVES:
I. To bank prospectively obtained serial liquid biospecimens for low and moderate risk of relapse patients annotated by patient level clinical data.
II. To bank prospectively collected, clinically annotated specimens for high risk patients and non-testicular primary patients in collaboration with Children's Oncology Group study AGCT 1531.
OUTLINE:
Patients undergo collection of blood every 3-6 months for up to 3 years.
Patients with newly diagnosed germ cell tumor
Inclusion Criteria:
Patients must have beta-human chorionic gonadotropin (beta- HCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration
Patients undergo collection of blood every 3-6 months for up to 3 years.
Other: Biomarker Analysis · Procedure: Blood Product Collection
Correlative study
Undergo collection of blood
Also known as: Collection, Blood Products
To estimate positive predictive value of miRNA 371 in early stage testicular seminoma and nonseminoma patients
Positive predictive value will be estimated using plasma miRNA 371 expression at relapse.
Time frame: Up to 3 years
To bank blood specimens of patients at low risk and moderate risk of relapse
10 ml whole blood will be collected at time points specified by the protocol.
Time frame: Up to 3 years
Showing the first 100 of 424 sites across 3 countries.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplasms, Germ Cell and Embryonal→
SWOG Cancer Research Network